Body Fluid Analysis Market by Product, Technology, Fluid Type, Application – Global Forecast to 2031

The global body fluid analysis market is projected to grow from USD 2.62 billion in 2026 to USD 3.65 billion by 2031 at a 6.9% CAGR. Growth is driven by rising neurological, musculoskeletal, infectious and reproductive health conditions, alongside advances in automated analyzers, clinical chemistry, flow cytometry, immunoassays and molecular diagnostics. Clinical diagnostics will lead by application, while clinical chemistry will hold the largest technology share. Asia Pacific is forecast to be the fastest-growing region, supported by healthcare modernization, aging populations and expanding diagnostic laboratory capacity.

Dublin, Aug. 17, 2026 (GLOBE NEWSWIRE) — The “Body Fluid Analysis Market by Product, Technology, Fluid Type, Application – Global Forecast to 2031” has been added to ResearchAndMarkets.com’s offering.

Body Fluid Analysis Market to Reach USD 3.65 Billion by 2031, Driven by Advanced Diagnostic Technologies

The global body fluid analysis market is projected to grow from USD 2.62 billion in 2026 to USD 3.65 billion by 2031, registering a compound annual growth rate (CAGR) of 6.9% during the forecast period. Market expansion is being supported by the rising global disease burden, increased demand for early disease detection, and continued advances in automated analyzers, flow cytometry, immunoassays, clinical chemistry, and molecular diagnostics.

The increasing prevalence of neurological disorders, including Alzheimer’s disease and Parkinson’s disease, is accelerating demand for cerebrospinal fluid (CSF) biomarker testing. At the same time, the growing incidence of musculoskeletal disorders and periprosthetic joint infections is expanding the clinical use of synovial fluid analysis. Improved accuracy, efficiency, and standardization in specialty body fluid testing are enabling healthcare providers to make more informed diagnostic and treatment decisions.

Clinical Diagnostics to Lead the Body Fluid Analysis Market

By application, the market is segmented into clinical diagnostics, forensics, and research. Clinical diagnostics is expected to represent the largest and fastest-growing application segment during the forecast period. Growth is attributed to the increasing use of body fluid testing to diagnose and monitor neurological disorders, infections, cancers, inflammatory conditions, and reproductive health disorders.

Hospitals and clinical laboratories routinely use flow cytometry, immunoassays, clinical chemistry, and molecular diagnostic technologies to evaluate CSF, pleural fluid, peritoneal fluid, synovial fluid, and other specialty body fluids. The growing focus on precision diagnostics, evidence-based clinical decision-making, and earlier disease detection is expected to sustain demand across routine healthcare settings.

Clinical Chemistry Expected to Capture the Largest Technology Share

Based on technology, the body fluid analysis market includes microscopic examination, clinical chemistry, flow cytometry, immunoassay, polymerase chain reaction (PCR), and other technologies. Clinical chemistry is likely to account for the largest share throughout the forecast period, supported by its established clinical utility, broad availability across healthcare facilities, and role in rapid diagnostic decision-making.

Continuous advances in automated chemistry analyzers, rising laboratory testing volumes, and demand for standardized diagnostic workflows are expected to support the worldwide adoption of clinical chemistry-based body fluid analysis. Innovation across PCR, flow cytometry, and immunoassay platforms will also contribute to greater sensitivity and efficiency in specialty fluid testing.

Asia Pacific to Record the Fastest Regional Growth Through 2031

The market is analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to register the highest regional CAGR from 2026 to 2031. Japan’s large aging population is increasing demand for CSF-based neurodegenerative disease diagnostics. China is expanding hospital laboratory capacity through national healthcare modernization programs, while India’s network of tertiary-care hospitals and private diagnostic centers is adopting automated body fluid analysis systems.

Competitive Landscape

Key companies operating in the global body fluid analysis market include Sysmex Corporation (Japan); F. Hoffmann-La Roche Ltd. (Switzerland); Danaher Corporation (US); bioMerieux SA (France); Abbott Laboratories (US); Thermo Fisher Scientific Inc. (US); QIAGEN N.V. (Netherlands); Revvity, Inc. (US); Siemens Healthineers AG (Germany); Becton, Dickinson and Company (US); HORIBA, Ltd. (Japan); Bio-Rad Laboratories, Inc. (US); and DiaSorin S.p.A. (Italy).

The competitive assessment examines market shares, growth strategies, product portfolios, acquisitions, agreements, product and service launches, and recent industry developments. It also evaluates emerging startups within the body fluid analysis market ecosystem. Leading companies assessed in detail include Danaher, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Becton, Dickinson and Company, and Abbott Laboratories.

Research Scope and Market Segmentation

The report categorizes the body fluid analysis market across the following segments:

• Product: Consumables and instruments
• Technology: Microscopic examination, clinical chemistry, flow cytometry, immunoassay, PCR, and other technologies
• Type: Collection devices and diagnostic products
• Fluid type: Cerebrospinal fluid, pleural fluid, peritoneal fluid, synovial fluid, semen, and pericardial fluid
• Application: Clinical diagnostics, forensics, and research
• End user: Hospital laboratories, diagnostic laboratories, forensic laboratories, academic and research institutes, and pharmaceutical and biotechnology companies
• Region: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

The research evaluates the principal market drivers, restraints, opportunities, and challenges. Key growth drivers include the rising global disease burden, increasing prevalence of infertility and other reproductive health conditions, and greater awareness of early disease detection. Market restraints include the high cost of instruments and consumables, shortages of skilled laboratory personnel, and the absence of standardized reimbursement structures.

Expansion across emerging economies and advances in diagnostic technologies present significant growth opportunities. However, suppliers and laboratories must address stringent and varying regulatory requirements, along with potential supply chain disruptions affecting reagents and testing kits. The report also provides detailed insights into research and development activities, upcoming technologies, new product launches, untapped geographies, investments, and commercially attractive regional markets.

Primary Research Participant Profile

• By company type: Tier 1-40%, Tier 2-30%, and Tier 3-30%
• By designation: C-level executives-27%, directors-18%, and others-55%
• By region: North America-51%, Europe-21%, Asia Pacific-18%, Latin America-6%, and Middle East & Africa-4%

Value for Market Stakeholders

The body fluid analysis market report provides established companies and new entrants with revenue estimates for the overall market and its subsegments. It supports competitive benchmarking, market positioning, and go-to-market strategy development while offering actionable intelligence on industry growth factors and commercial risks. Stakeholders can use the findings to assess product development opportunities, prioritize regional expansion, evaluate market diversification strategies, and better understand the evolving competitive landscape.

Key Attributes:

Key Topics Covered:

MARKET DYNAMICS

• Drivers
  • Growing global infectious disease, inflammatory disease, and cancer burden necessitating body fluid analysis
  • Increasing prevalence of reproductive health conditions and infertility
  • Growing awareness of early disease detection
• Challenges
  • Restraints
    • Limited and inconsistent reimbursement for advanced body fluid testing
    • High cost of instruments and consumables
    • Shortage of skilled laboratory personnel
  • Stringent and varying regulatory requirements
  • Supply chain disruptions for reagents and kits
• Case Studies
  • Implementation of automated CSF Alzheimer’s biomarker testing using Roche Elecsys assays
  • Implementation of automated body fluid cell counting using Beckman Coulter UniCel DxH Series
  • Point-of-care testing for pleural, peritoneal, and CSF analysis
• Industry Trends
  • Trends/disruptions impacting customers’ businesses
• Opportunities
  • Expansion potential across emerging economies
  • Advancements in diagnostic technologies

COMPANY PROFILES

• Danaher
• F. Hoffmann-La Roche Ltd
• Becton, Dickinson and Company (BD)
• Abbott
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• bioMerieux
• Sysmex Corporation
• Bio-Rad Laboratories
• QIAGEN
• Revvity
• DiaSorin S.p.A.
• HORIBA, Ltd.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Vircell S.L.
• Fujirebio
• Erba Group
• Guangzhou Wondfo Biotech Co., Ltd.
• Meso Scale Diagnostics, LLC
• Randox Laboratories Ltd.
• Amprion Diagnostics
• Atila BioSystems
• Quanterix
• Alamar Biosciences
• GeneProof

For more information about this report visit https://www.researchandmarkets.com/r/cb1sar

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Body Fluid Analysis Market

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900